Back to top
more

Zimmer Biomet (ZBH)

(Real Time Quote from BATS)

$123.07 USD

123.07
1,051,740

-0.93 (-0.75%)

Updated Apr 16, 2024 03:45 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (102 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.

Smith+Nephew (SNN) Expands in Australia With New Alliance

by Zacks Equity Research

The latest partnership allows Smith+Nephew (SNN) to complement its existing implant range with the cutting-edge navigation technology of NAVBIT.

Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Tenet (THC) Divests Six Hospitals, Sustains Divestiture Spree

by Zacks Equity Research

Tenet Healthcare (THC) completes the sale of six California hospitals, four to UCI Health and two to Adventist Health, to refine the portfolio and reduce debt burden.

Indrajit Bandyopadhyay headshot

5 Medical Product Stocks to Buy Amid Industry Challenges

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, RMD, ZBH, PODD and LNTH are well-poised to gain from the favorable factors.

Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH), led by expansion in the knee business and recovery across the business.

Cardinal Health (CAH) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.

Fresenius Medical (FMS) Divests Assets to Optimize Portfolio

by Zacks Equity Research

Fresenius Medical's (FMS) latest asset divestments reflect a milestone in its portfolio optimization program and are likely to improve profitability.

Zimmer Biomet (ZBH) Rides on ROSA Uptake, Favorable Trend

by Zacks Equity Research

Focused execution of Zimmer Biomet's (ZBH) global sales teams amid a stable global musculoskeletal market helps accelerate global sales.

Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Universal Health (UHS) Q4 Earnings Beat on Adjusted Admissions

by Zacks Equity Research

Universal Health (UHS) expects net revenues between $15.411 billion and $15.706 billion for 2024, which indicates 8.9% year-over-year growth.

Select Medical (SEM) Q4 Earnings Beat on Patient Admissions

by Zacks Equity Research

Select Medical's (SEM) Q4 results reflect strong segmental contribution, aided by higher patient days and visits. Management expects 2024 adjusted EBITDA to be $830-$880 million, up from the 2023 reported figure of $807.4 million.

Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now

by Zacks Equity Research

Strategic plans to drive the Knee business bode well for Zimmer Biomet (ZBH).

Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zimmer Biomet (ZBH) Q4 Earnings Top Estimates, Margins Grow

by Zacks Equity Research

Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER in the fourth quarter.

Zimmer (ZBH) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zimmer Biomet (ZBH) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 2.33% and 0.57%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Curious about Zimmer (ZBH) Q4 Performance? Explore Wall Street Estimates for Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of Zimmer (ZBH) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

What's in Store for Zimmer Biomet (ZBH) in Q4 Earnings?

by Zacks Equity Research

Zimmer Biomet (ZBH) is expected to have gained from the uptake of Persona OsseoTi Keel Tibia for Cementless Knee Replacement in the fourth quarter.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

3 Reasons to Hold Zimmer Biomet (ZBH) Stock in Your Portfolio

by Zacks Equity Research

Zimmer Biomet's (ZBH) focus on emerging markets raises optimism about the stock.

Why Is Zimmer (ZBH) Up 10.8% Since Last Earnings Report?

by Zacks Equity Research

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Zimmer Biomet (ZBH) for Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH), driven by a recovery in business and an expanding global footprint.

Why Zimmer Biomet (ZBH) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zimmer Biomet's (ZBH) Knee Sales Robust, Macro Woes Hurt

by Zacks Equity Research

Zimmer Biomet (ZBH) is working to strengthen its foothold in emerging markets that provide long-term opportunities for growth.

Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Fall

by Zacks Equity Research

Zimmer Biomet (ZBH) gains from solid strategic execution and increasing traction in innovations in the third quarter.